| Literature DB >> 27686681 |
Rebekah L Scheuerle1, Richard A Kendall2, Catherine Tuleu2, Nigel K H Slater3, Stephen E Gerrard3.
Abstract
An in vitro simulation system was developed to study the effect of an infant's peristaltic tongue motion during breastfeeding on oral rapidly disintegrating tablets in the mouth, for use in rapid product candidate screening. These tablets are being designed for use inside a modified nipple shield worn by a mother during breastfeeding, a proposed novel platform technology to administer drugs and nutrients to breastfeeding infants. In this study, the release of a model compound, sulforhodamine B, from tablet formulations was studied under physiologically relevant forces induced by compression and rotation of a tongue mimic. The release profiles of the sulforhodamine B in flowing deionized water were found to be statistically different using 2-way ANOVA with matching, when tongue mimic rotation was introduced for 2 compression levels representing 2 tongue strengths (p = 0.0013 and p < 0.0001 for the lower and higher compression settings, respectively). Compression level was found to be a significant factor for increasing model compound release at rotational rates representing nonnutritive breastfeeding (p = 0.0162). This novel apparatus is the first to simulate the motion and pressures applied by the tongue and could be used in future infant oral product development.Entities:
Keywords: drug delivery systems; in vitro models; oral drug delivery; pediatric; physical characterization
Mesh:
Substances:
Year: 2016 PMID: 27686681 PMCID: PMC5157687 DOI: 10.1016/j.xphs.2016.08.006
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534
Figure 1Nipple shield delivery system illustration.www.justmilk.org.
Figure 2Process flow diagram of the tongue mimic system experimental apparatus.
Figure 3Illustration of the tongue mimic (a) where arrow 1 represents rotation which the tongue mimic is capable of and arrow 2 represents the plausible movement of the palate mimic for adjusting the amount of compression exposed to the tablet; dimensions of the tongue mimic shaft used in the TMS shown from the top (a) and side (b).
Pressure Characterization of Tongue Mimic System Settings
| Compression Setting | Rotational Rate (Rotation/min) | Average Peak Pressure (KPa) | Potential Clinical Analogue Conditions to the Measured Pressures | ||
|---|---|---|---|---|---|
| Setting 1 (C1) | (R1) 58.5 ± 0.3 | 18 | 51 ± 2 | 3 | Apical tongue region of a young low birthweight infant |
| Setting 1 (C1) | (R2) 105.4 ± 0.5 | 18 | 105 ± 6 | 3 | Apical tongue region |
| Setting 2 (C2) | (R1) 58.5 ± 0.3 | 24 | 153 ± 7 | 3 | Apical tongue region |
| Setting 2 (C2) | (R2) 105.4 ± 0.5 | 24 | 260 ± 18 | 3 | Posterior tongue region |
Per rotation based on PEEK tablet peak pressure results for the first 10 rotations of 3 trials.
Based on clinical data reported by Niikawa et al., 2012.
Laboratory-Manufactured Tablet Details (Scheuerle et al., 2015)
| Composition | ||||
|---|---|---|---|---|
| Chemical | Role | w/w | Grade | Manufacturer |
| Sulforhodamine B (Sigma) | Model compound | 2.6 | 75% Purity | Sigma-Aldrich, Dorset, UK |
| Lactose (SuperTab 14SD) | Filler | 91.4 | Ph. Eur | DFE Pharma, Goch, Germany |
| Sodium starch glycolate (Explotab CLV) | Superdisintegrant | 3.0 | Typ (A) Ph. Eur | Mendell GmbH, Volklingen, Germany |
| Croscarmellose sodium (Ac-Di-Sol) | Superdisintegrant | 2.0 | Ph. Eur | FMC Biopolymer, Girvan, UK |
| Magnesium stearate | Lubricant | 1.0 | Technical Grade | Sigma-Aldrich, Dorset, UK |
n = 10.
n = 6.
Figure 4Pressure measurements for the median of 3 trials for compression setting 1 (a) and compression setting 2 (b) for the duration of each trial (i) and for the first 10 s of each trial (ii); graphed with ±1 s accuracy.
Figure 5Release profiles for SB for compression setting 1 (a); compression setting 2 (b); and rotational rate 1 (c), 2 (d), and 3 (e); n = 3; graphed with ±10 s accuracy; error bars represent standard error.
Peak Pressure Results of Tongue Mimic System Experiment
| Compression Setting | Rotational Rate (Rotation/min) | Average Peak Pressure (KPa) | ||
|---|---|---|---|---|
| Setting 1 (C1) | (R1) 58.5 ± 0.3 | 18 | 188 ± 36 | 3 |
| Setting 1 (C1) | (R2) 105.4 ± 0.5 | 18 | 197 ± 19 | 3 |
| Setting 2 (C2) | (R1) 58.5 ± 0.3 | 24 | 134 ± 12 | 3 |
| Setting 2 (C2) | (R2) 105.4 ± 0.5 | 24 | 188 ± 14 | 3 |
For each trial using SB tablets.